Clinical Trial

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated October 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to learn about the diagnostic performance of a novel Neoantigen-Reactive CD8+ T cell (NART) technology detecting minimal residual disease (MRD) in postoperative surveillance of pancreatic cancer. The main question it aims to answer is: Is NART a sensitive and accurate detection for MRD? Participants are required to undergo periodic blood sampling and imaging examinations as the protocol specifies.
Trial Details
NCT Number NCT06941987
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Minimal Residual Disease, Pancreatic Cancer Resectable
Enrollment 66 participants
Start Date 2025-04-20
Primary Completion 2025-10-20 (estimated)
Study Completion 2027-10-20 (estimated)
Updated on ClinicalTrials.gov 2025-04-24